Suzhou Fushilai Pharmaceutical Co., Ltd.

Equities

301258

CNE1000058W2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
22.49 CNY +1.03% Intraday chart for Suzhou Fushilai Pharmaceutical Co., Ltd. -9.71% -30.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2024. CI
Suzhou Fushilai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Suzhou Fushilai Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Fushilai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Suzhou Fushilai Pharmaceutical Co., Ltd. CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for 2022, Payable on 08 June 2023 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2023. CI
Fushilai Pharmaceutical to Apply for 375 Million Yuan Credit Lines This Year MT
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves Management Appointments CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Final Announces Cash Dividend on A Shares for 2021, Payable on June 8, 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Proposes Profit Distribution for 2021 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.107036 billion. CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has filed an IPO. CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has withdrawn its IPO. CI
Chart Suzhou Fushilai Pharmaceutical Co., Ltd.
More charts
Suzhou Fushilai Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The Company's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The Company mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 301258 Stock
  4. News Suzhou Fushilai Pharmaceutical Co., Ltd.
  5. Fushilai Pharmaceutical to Apply for 375 Million Yuan Credit Lines This Year